Sandoz launches ustekinumab biosimilar in Europe
Sandoz has announced the European launch of Pyzchiva, a ustekinumab biosimilar approved for the treatment of several autoimmune conditions including…
Sandoz has announced the European launch of Pyzchiva, a ustekinumab biosimilar approved for the treatment of several autoimmune conditions including…
AbbVie has made a licence agreement with FutureGen Biopharmaceutical to develop a next-generation therapy, FG-M701, for inflammatory bowel disease (IBD).…
I-Mab has announced a collaboration and supply agreement with Bristol Myers Squibb (BMS) to assess givastomig in combination with nivolumab…
AltruBio has secured $225m in an oversubscribed Series B financing round to progress the clinical development of its new immune…
CinDome Pharma has secured $40m in a Series B financing extension round aimed at progressing the development of deudomperidone (CIN-102)…
Novartis has received a US Food and Drug Administration (FDA) approval for the label expansion of its peptide receptor radionuclide…
Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has become the first drug to be approved by the US Food and Drug Administration (FDA)…
BeiGene has announced the acceptance of a biologics licence application (BLA) by the US Food and Drug Administration (FDA) for…
Netherland-based Polpharma Biologics has released top line results from a pharmacokinetic (PK) and pharmacodynamic (PD) study of its biosimilar candidate…
Celltrion Healthcare Canada has announced that its Remsima SC, a subcutaneous version of its infliximab biosimilar, has obtained approval for…